---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000144"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:25:35.902308+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine CMO Baisong Mei steps down; separation terms outlined

## Summary
- Baisong Mei to step down as CMO effective Dec 31, 2024; transition period ends Jan 31, 2025.
- Separation agreement provides 12 months base salary, COBRA contributions, and potential 2024 bonus.
- Vested stock option exercise extended to Dec 31, 2025; unvested RSUs vest through 90 days post-separation.
- Agreement includes standard release, non-disparagement, and confidentiality clauses.

## SEC filing metadata
- accession: 0001650664-24-000144
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000144/0001650664-24-000144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000144/edit-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000144
- JSON: https://secwatch.observer/filing/0001650664-24-000144.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.